These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23042772)

  • 1. Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.
    Okubo S; Nishiuma S; Kobayashi N; Taketsuna M; Taniai H
    Jpn J Clin Oncol; 2012 Nov; 42(11):1043-53. PubMed ID: 23042772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan.
    Ioka T; Katayama K; Tanaka S; Takakura R; Ashida R; Kobayashi N; Taniai H
    Jpn J Clin Oncol; 2013 Feb; 43(2):139-45. PubMed ID: 23275642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
    Suzuki E; Furuse J; Ikeda M; Okusaka T; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Shimizu S; Kojima Y; Hagihara A
    Oncology; 2010; 79(1-2):39-45. PubMed ID: 21063134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
    Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Okubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nakajima A
    Hepatogastroenterology; 2011; 58(105):26-30. PubMed ID: 21510281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
    Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
    Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for biliary tract cancer in Japan.
    Okusaka T
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):51-3. PubMed ID: 12577234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.
    Yukisawa S; Ishii H; Matsuyama M; Kuraoka K; Takano K; Kamei A; Ozaka M
    Jpn J Clin Oncol; 2011 Jan; 41(1):76-80. PubMed ID: 20926412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Valle J; Wasan H; Palmer DH; Cunningham D; Anthoney A; Maraveyas A; Madhusudan S; Iveson T; Hughes S; Pereira SP; Roughton M; Bridgewater J;
    N Engl J Med; 2010 Apr; 362(14):1273-81. PubMed ID: 20375404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
    Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
    Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
    Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Ohubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nahajima A
    Hepatogastroenterology; 2011; 58(106):270-4. PubMed ID: 21661380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief commentary: largest randomized trial of biliary tract cancer treatment with cisplatin plus gemcitabine versus gemcitabine alone: an excellent opportunity to evaluate the prognostic value of tumor marker CA 19-9.
    Copur MS; Obermiller A
    Clin Colorectal Cancer; 2011 Mar; 10(1):70-1. PubMed ID: 21609939
    [No Abstract]   [Full Text] [Related]  

  • 16. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
    Katayose Y; Ohtsuka H; Kitamura Y; Masuda K; Nakagawa K; Yamamoto K; Yoshida H; Onogawa T; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
    Hepatogastroenterology; 2012 May; 59(115):691-5. PubMed ID: 22469710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.
    Matsuyama M; Ishii H; Furuse J; Ohkawa S; Maguchi H; Mizuno N; Yamaguchi T; Ioka T; Ajiki T; Ikeda M; Hakamada K; Yamamoto M; Yamaue H; Eguchi K; Ichikawa W; Miyazaki M; Ohashi Y; Sasaki Y
    Invest New Drugs; 2015 Apr; 33(2):490-5. PubMed ID: 25502982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
    Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
    J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gemcitabine is an effective single agent for the treatment of advanced biliary tract cancer].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1365-9. PubMed ID: 16969042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
    Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.